跳至主要内容
临床试验/NCT07624578
NCT07624578撤回不适用

Evaluation of 68Ga-PSMA PET-CT in the Initial Staging of Advanced Renal Cell Carcinomas - A Prospective, Multicentre, Open-label Study

Assistance Publique Hopitaux De Marseille0 个研究点开始时间: 2020年1月1日最近更新:

试验速览

阶段
不适用
状态
撤回

研究概览

简要总结

Kidney cancer in adults is the seventh leading cause of cancer-related death in France. Early and accurate imaging of the primary tumour and the identification of metastatic sites are major prognostic factors that are crucial for determining the appropriate stage-specific treatment. However, the diagnosis of sub-centimetre metastatic lymph nodes and occult metastatic lesions remains difficult with current imaging methods. Recent publications have shown promising results for 68Ga-PSMA PET-CT in the detection of metastases from renal cell carcinoma (RCC). It is therefore necessary to develop a new, more sensitive and specific imaging method to detect occult metastatic foci, enabling the earlier initiation of specific systemic or local treatment, and thereby improving survival in these patients or even achieving prolonged remission in oligometastatic cases Experience and acceptability of a new organisational model in primary care: participatory multi-professional health centres

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age ≥ 18 years, enrolled in a social security scheme.
  • Signed informed consent form.
  • Patient newly diagnosed with localised intermediate- or high-risk renal cell carcinoma (UISS prognostic system) or metastatic renal cancer (M1 according to TNM staging) with histological evidence (biopsy or surgical specimen).
  • Recent conventional imaging work-up (dated no more than 1 month prior to the 68Ga-PSMA PET scan):
  • Brain CT, chest and abdominal-pelvic CT with iodine injection, including arterial, portal and late phases;
  • Bone scan (BS);

排除标准

  • Pregnant or breastfeeding women;
  • History of another known progressive neoplasm within the past two years

研究者

申办方类型
Other
责任方
Sponsor

相似试验